Manufacturer of Controlled Substances; Notice of Application, 29717-29718 [E9-14708]
Download as PDF
<![CDATA[
29717
Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices
Import Investigations, U.S. International
Trade Commission, telephone (202)
205–2579.
INTERNATIONAL TRADE
COMMISSION
[Inv. No. 337–TA–679]
Authority: The authority for institution of
this investigation is contained in section 337
of the Tariff Act of 1930, as amended, and
in section 210.10 of the Commission’s Rules
of Practice and Procedure, 19 CFR 210.10
(2009).
In the Matter of Certain Products
Advertised as Containing Creatine
Ethyl Ester; Notice of Investigation
AGENCY: U.S. International Trade
Commission.
ACTION: Institution of investigation
pursuant to 19 U.S.C. 1337.
SUMMARY: Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on May
20, 2009, under section 337 of the Tariff
Act of 1930, as amended, 19 U.S.C.
1337, on behalf of UNeMed Corporation
of Omaha, Nebraska. Supplements to
the Complaint were filed on June 5,
2009, June 8, 2009 and June 10, 2009.
The complaint, as supplemented,
alleges violations of section 337(a)(1)(A)
based upon the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain products
advertised as containing creatine ethyl
ester by reason of false advertising in
violation of Section 43(a) of the Lanham
Act, 15 U.S.C. 1125(a)(1)(B) and the
Nebraska Uniform Deceptive Trade
Practices Act, R.R.S. Neb. § 87–302
(2008), the threat or effect of which is
to destroy or substantially injure an
industry in the United States.
The complainant requests that the
Commission institute an investigation
and, after the investigation, issue an
exclusion order and cease and desist
orders.
The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street, SW., Room
112, Washington, DC 20436, telephone
202–205–2000. Hearing impaired
individuals are advised that information
on this matter can be obtained by
contacting the Commission’s TDD
terminal on 202–205–1810. Persons
with mobility impairments who will
need special assistance in gaining access
to the Commission should contact the
Office of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its Internet server at https://
www.usitc.gov. The public record for
this investigation may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
FOR FURTHER INFORMATION CONTACT:
Jeffrey T. Hsu, Esq., Office of Unfair
ADDRESSES:
VerDate Nov<24>2008
16:15 Jun 22, 2009
Jkt 217001
Scope of Investigation: Having
considered the complaint, the U.S.
International Trade Commission, on
June 15, 2009, ordered that—
(1) Pursuant to subsection (b) of
section 337 of the Tariff Act of 1930, as
amended, an investigation be instituted
to determine whether there is a
violation of subsection (a)(1)(A) of
section 337 in the importation into the
United States, the sale for importation,
or the sale within the United States after
importation of certain products
advertised as containing creatine ethyl
ester by reason of false advertising, the
threat or effect of which is to destroy or
substantially injure an industry in the
United States;
(2) For the purpose of the
investigation so instituted, the following
are hereby named as parties upon which
this notice of investigation shall be
served:
(a) The complainant is—UNeMed
Corporation, 986099 Nebraska Medical
Center, Omaha, NE 68198–6099.
(b) The respondents are the following
entities alleged to be in violation of
section 337, and are the parties upon
which the complaint is to be served:
Bodyonics, Ltd., 140 Lauman Lane,
Hicksville, NY 11801.
Engineered Sports Technology, Inc.,
4250 Alafaya Trail, Oviedo, FL 32765.
Proviant Technologies, Inc., 309 West
Hensley Road, Champaign, IL 61822–
8401.
NRG–X Labs, 10636 West Highway 72
#1001, Bentonville, AR 72712.
San Corporation, 716 North Ventura
Road #431, Oxnard, CA 93030.
(c) The Commission investigative
attorney, party to this investigation, is
Jeffrey T. Hsu, Esq., Office of Unfair
Import Investigations, U.S. International
Trade Commission, 500 E Street, SW.,
Suite 401, Washington, DC 20436; and
(3) For the investigation so instituted,
Paul J. Luckern, Chief Administrative
Law Judge, U.S. International Trade
Commission, shall designate the
presiding Administrative Law Judge.
Responses to the complaint and the
notice of investigation must be
submitted by the named respondents in
accordance with section 210.13 of the
Commission’s Rules of Practice and
Procedure, 19 CFR 210.13. Pursuant to
19 CFR 201.16(d) and 210.13(a), such
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
responses will be considered by the
Commission if received not later than 20
days after the date of service by the
Commission of the complaint and the
notice of investigation. Extensions of
time for submitting responses to the
complaint and the notice of
investigation will not be granted unless
good cause therefor is shown.
Failure of a respondent to file a timely
response to each allegation in the
complaint and in this notice may be
deemed to constitute a waiver of the
right to appear and contest the
allegations of the complaint and this
notice, and to authorize the
administrative law judge and the
Commission, without further notice to
the respondent, to find the facts to be as
alleged in the complaint and this notice
and to enter an initial determination
and a final determination containing
such findings, and may result in the
issuance of an exclusion order or a cease
and desist order or both directed against
a respondent.
By order of the Commission.
Issued: June 17, 2009.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E9–14670 Filed 6–22–09; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 8, 2009,
Chattem Chemicals Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
letter to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic class of
controlled substances listed in schedule
II:
Drug
Methadone (9250) ........................
Methadone intermediate (9254) ...
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
E:\FR\FM\23JNN1.SGM
23JNN1
29718
Federal Register / Vol. 74, No. 119 / Tuesday, June 23, 2009 / Notices
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14708 Filed 6–22–09; 8:45 am]
Springfield, Virginia 22152; and must be
filed no later than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator/Deputy Chief
of Operation, Office of Diversion Control,
Drug Enforcement Administration.
[FR Doc. E9–14697 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Cooperative Research
Group on Clean Diesel V
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 13, 2009,
Austin Pharma LLC., 811 Paloma Drive,
Suite A, Round Rock, Texas 78665–
2402, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
BILLING CODE 1505–01–D
DEPARTMENT OF JUSTICE
I
I
I
II
II
II
II
II
II
II
II
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
In reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol as a synthetic
intermediate. This controlled substance
will be further synthesized to bulk
manufacture a synthetic THC (7370). No
other activity for this drug code is
authorized for this registration.
Any other such applicant, and any
person who is presently, registered with
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
16:15 Jun 22, 2009
[FR Doc. Z9–10358 Filed 6–22–09; 8:45 am]
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Nabilone (7379) ............................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Levo-alphacetylmethadol (9648) ..
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
VerDate Nov<24>2008
Correction
In notice document E9–10358
appearing on page 21403 in the issue of
May 7, 2009, make the following
correction:
On page 21403, in the first column, in
the second line from the bottom,
‘‘Auburn Hills, NI’’ should read
‘‘Auburn Hills, MI’’.
Jkt 217001
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations 1301.34(a),
this is notice that on May 18, 2009,
Aptuit, 10245 Hickman Mills Drive,
Kansas City, Missouri 64137, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Marihuana (7360), a basic class of
controlled substance listed in schedule
I.
The company plans to import a
finished pharmaceutical product
containing cannabis extracts in dosage
form for packaging for a clinical trial
study.
Any bulk manufacturer who is
presently, or is applying to be,
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 23, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import the basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–14693 Filed 6–22–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations 1301.34(a),
this is notice that on May 28, 2009,
Boehringer Ingelheim Chemicals, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
E:\FR\FM\23JNN1.SGM
23JNN1
]]>Agencies
[Federal Register Volume 74, Number 119 (Tuesday, June 23, 2009)]
[Notices]
[Pages 29717-29718]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-14708]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 8, 2009, Chattem
Chemicals Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by letter to the Drug Enforcement
Administration (DEA) as a bulk manufacturer of the basic class of
controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methadone (9250)........................... II
Methadone intermediate (9254).............. II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
[[Page 29718]]
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 24, 2009.
Dated: June 15, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-14708 Filed 6-22-09; 8:45 am]
BILLING CODE 4410-09-P
